Vanguard Group
WHWK

Vanguard Group’s Whitehawk Therapeutics WHWK Stock Holding History

Vanguard Group’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.85M Buy
1,590,117
+247,210
+18% +$567K ﹤0.01% 3353
2025
Q3 		$2.55M Buy
1,342,907
+27,622
+2% +$50.8K ﹤0.01% 3501
2025
Q2 		$2.46M Buy
1,315,285
+549,293
+72% +$956K ﹤0.01% 3466
2025
Q1 		$1.36M Hold
765,992
– – ﹤0.01% 3613
2024
Q4 		$2.42M Hold
765,992
– – ﹤0.01% 3502
2024
Q3 		$1.58M Hold
765,992
– – ﹤0.01% 3629
2024
Q2 		$1.12M Sell
765,992
-90,844
-11% -$168K ﹤0.01% 3756
2024
Q1 		$2M Sell
856,836
-2,861
-0.3% -$5.51K ﹤0.01% 3592
2023
Q4 		$1.74M Buy
859,697
+88,313
+11% +$371K ﹤0.01% 3651
2023
Q3 		$3.73M Buy
771,384
+9,480
+1% +$55.1K ﹤0.01% 3366
2023
Q2 		$5.21M Sell
761,904
-9,822
-1% -$76.4K ﹤0.01% 3278
2023
Q1 		$5.59M Buy
771,726
+32,985
+4% +$352K ﹤0.01% 3249
2022
Q4 		$9.48M Sell
738,741
-2,428
-0.3% -$31.7K ﹤0.01% 2969
2022
Q3 		$10.5M Sell
741,169
-92,658
-11% -$1.22M ﹤0.01% 2935
2022
Q2 		$10.3M Buy
833,827
+73,544
+10% +$1.09M ﹤0.01% 2978
2022
Q1 		$12.9M Sell
760,283
-1,190
-0.2% -$22.8K ﹤0.01% 3017
2021
Q4 		$18.4M Buy
761,473
+643,196
+544% +$16.2M ﹤0.01% 2883
2021
Q3 		$3.47M Sell
118,277
-21
-0% -$640 ﹤0.01% 3854
2021
Q2 		$3M Buy
118,298
+3,284
+3% +$75K ﹤0.01% 3838
2021
Q1 		$2.23M Sell
115,014
-65,758
-36% -$1.51M ﹤0.01% 3838
2020
Q4 		$2.66M Buy
180,772
+102,355
+131% +$2.19M ﹤0.01% 3587
2020
Q3 		$1.76M Buy
78,417
+1,586
+2% +$33.4K ﹤0.01% 3522
2020
Q2 		$1.44M Sell
76,831
-2,763
-3% -$36.1K ﹤0.01% 3523
2020
Q1 		$657K Sell
79,594
-199
-0.2% -$1.83K ﹤0.01% 3611
2019
Q4 		$746K Hold
79,793
– – ﹤0.01% 3701
2019
Q3 		$813K Sell
79,793
-6,933
-8% -$76.8K ﹤0.01% 3701
2019
Q2 		$1.18M Buy
86,726
+7,250
+9% +$110K ﹤0.01% 3625
2019
Q1 		$1.07M Buy
79,476
+27,674
+53% +$1.19M ﹤0.01% 3609
2018
Q4 		$1.32M Sell
51,802
-20,068
-28% -$639K ﹤0.01% 3485
2018
Q3 		$3.33M Buy
+71,870
New +$4.03M ﹤0.01% 3370

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Vanguard Group's WHWK Position: Q4 2025 in Review

Vanguard Group increased its Whitehawk Therapeutics (WHWK) stake by 18% in Q4 2025, buying an estimated $567K and bringing the position to 1,590,117 shares worth $3.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3353.

Vanguard Group first reported a position in WHWK in Q3 2018 and has held it in 30 quarters since. The position peaked at $18.4M in Q4 2021. 48 funds tracked by Wall St. Rank hold WHWK as of Q4 2025.

  • Vanguard Group held 1,590,117 shares of Whitehawk Therapeutics worth $3.85M as of Q4 2025.
  • Vanguard Group bought 247,210 Whitehawk Therapeutics shares in Q4 2025, an estimated $567K.
  • Whitehawk Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3353 holding.
  • Vanguard Group first reported a position in Whitehawk Therapeutics in Q3 2018 and has held it in 30 quarters since.
  • Vanguard Group's Whitehawk Therapeutics position peaked at $18.4M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.